Recent advances in immunotherapy and molecular targeted therapy | ResearchBunny

Index

Abstract

Gastric cancer is a significant global health concern, ranking fourth in both incidence and mortality. Despite advancements in chemotherapy, median survival remains limited (12-15 months). This review examines recent progress in immunotherapy and molecular targeted therapies for gastric cancer, focusing on immune checkpoint inhibitors (ICIs) and their combinations with cytotoxic and targeted agents. Clinical trials demonstrate potential benefits, particularly with anti-PD-1/PD-L1 inhibitors, and ongoing research explores combination strategies to improve outcomes.

Publisher

Future Science OA

Published On

Mar 17, 2023

Authors

Yuri Yoshinami, Hirokazu Shoji

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

F. Ye, S. Dewanjee, et al.

Medicine and Health

Advances in Photodynamic Therapy for the Treatment of Actinic Keratosis and Nonmelanoma Skin Cancer: A Narrative Review

A. S. Farberg, W. Justin, et al.

Engineering and Technology

Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges

R. P. Singh, A. Natarajan, et al.

Medicine and Health

Randomised controlled trial and economic evaluation of a targeted cancer awareness intervention for adults living in deprived areas of the UK

Y. Moriarty, M. Lau, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs—just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny